Medical Device Corporate Integrity Agreements: What the Settlement Requires Next

A medical device corporate integrity agreement requires a company to carry out compliance duties agreed with the Department of Health and Human Services Office of Inspector General, often alongside a civil fraud settlement. At Advanced Bionics, allegations of misleading implant testing led to independent review of the work behind submissions to the Food and Drug Administration. Those duties can also reach physician arrangements, hospital claims and certifications by company leadership. The important question is whether the work behind those reports matches what management says happened.

What a Medical Device Corporate Integrity Agreement Requires

A medical device corporate integrity agreement sets obligations for the company’s future conduct. In exchange for the company accepting those obligations, the Inspector General agrees not to seek its exclusion from Medicare, Medicaid and other federal health care programs.

The Inspector General’s explanation of corporate integrity agreements describes a five-year period, implementation and annual reports, and independent reviews. Examples of implementation duties include hiring a compliance officer and restricting employment of people excluded from federal programs. The agreement also contains provisions allowing monetary penalties for failures to comply.

The reporting continues after the settlement. The Inspector General closes an agreement after receiving and reviewing the final report. Terms can differ: Shreveport Prosthetics had a three-year Integrity Agreement.

Why the Review Reaches Beyond the Manufacturer

The physician choosing an implant, the company selling it and the hospital billing for the surgery can hold different parts of the same transaction. The Inspector General calls implantable devices physician preference items because the physician may make or strongly influence the choice of brand and device type. The hospital or surgery center buys the product.

Consignment adds another handoff. A manufacturer may own an implant sitting at the hospital until it is used. The representative may manage the inventory and the trays that give the surgeon a choice of sizes during the operation. For most implanted devices, Medicare packages the device into payment for the procedure or hospital stay.

That structure explains why a review of physician payments can matter to a hospital claim. The manufacturer pays the physician, the physician influences product selection, and the institution bills for the procedure. The financial arrangement and the claim may sit in different businesses. Patients undergo the procedures, and taxpayers pay the government claims. An insider who knows how the implant was selected can supply the connection between the payment and the claim.

Independent Reviews Follow the Alleged Failure

Independent review can examine the manufacturer’s technical submissions or the provider’s claims. Advanced Bionics and Sanford show how different those assignments can be, even when both accompany a device-related settlement.

Advanced Bionics and the Testing Behind FDA Submissions

Advanced Bionics’ agreement required independent review of the activities and processes used to prepare or submit premarket approval applications to the Food and Drug Administration, including the performance standards relevant to those applications. Its December 2022 settlement announcement also describes a risk assessment program and compliance certifications from key managers and the board of directors.

The underlying allegations explain that focus. The government alleged that the cochlear implant manufacturer claimed its Neptune and Naida processors met an emissions standard while failing to test them in the required worst-case configurations. It allegedly shielded components during testing and then sought reimbursement from Medicare, Medicaid and other federal healthcare programs for the devices.

For an engineer, the meaningful comparison is the configuration tested against the configuration described to the regulator. For the manager certifying compliance, it is the work supporting the submission. The same passing result can look very different to the person who saw how the test was run. Here the review reached the process that produced the result, and the certifications reached beyond the compliance department to company leadership.

Sanford and the Claims Behind Spinal Surgery

Sanford’s agreement required an Independent Review Organization to review Medicare and Medicaid claims at Sanford Medical Center. The October 2019 settlement announcement also required a compliance program, risk assessment and compliance-related certifications from the medical center’s board and key executives.

Sanford agreed to pay $20.25 million over allegations that it continued billing for surgeries despite repeated warnings about a neurosurgeon’s financial interest in the devices and medically unnecessary procedures. The surgeon allegedly profited from implants distributed through his physician-owned business. Colleagues and others had allegedly raised the concerns inside the hospital.

The review therefore reached the claims where the alleged device incentives became government payments. The hospital also prohibited its physicians from profiting from their use of medical devices at Sanford. That change addressed the connection between product selection and personal income that the government had challenged.

Physician Arrangements and the Work Behind Payments

Where an agreement calls for review of physician arrangements, the review can compare paid services with work actually performed. Biotronik’s 2022 physician-training settlement illustrates the payment records worth testing: the government alleged payments for training that never occurred.

Reports and Certifications Put the Response on Paper

The Inspector General’s reporting framework calls for an implementation report, annual reports and notice of specified problems, including overpayments, reportable events and ongoing investigations or legal proceedings. Those reports give the agency an account of compliance activity after the original resolution.

The board certifications in Advanced Bionics and Sanford put responsibility for that account at the top of each organization. An engineer may know how a test was configured. A claims reviewer may know which surgeries were billed. The executive signing a certification is answering for the compliance work that concerns those records.

A compliance employee may know that a warning reached management while the same payments or claims continued. The allegations in Sanford and Biotronik show why that comparison matters: warnings had allegedly reached the business before the government resolved the cases. The presence of a compliance department did not make the warnings disappear from the story.

Aesculap Refused an Agreement After Its Settlement

Aesculap Implant Systems refused a corporate integrity agreement on November 17, 2025, the same day the Justice Department announced its $38.5 million civil settlement. The government alleged that Aesculap sold Vega knee implants while knowing they would fail prematurely and failed to record, track or report adverse events adequately.

The civil allegations also concerned payments to a surgeon who had experienced problems with the implant. The alleged benefits included consulting payments, international travel and entertainment intended to induce continued use and recommendations. Product complaints and physician payments met in the same case.

The Inspector General recorded the refusal under heightened scrutiny for ten years and reserved the right to exclude the company. Exactech and Innovasis also refused agreements.

What an Actual Agreement Breach Looked Like

Exactech’s earlier enforcement history shows a documented failure to perform integrity-agreement duties. On June 9, 2014, it paid a $15,000 stipulated penalty for failing to screen employees and contractors against exclusion lists, distribute revised policies and provide its code of conduct and anti-kickback policies to parties to covered arrangements.

Those were specific missing tasks: screening people, distributing changes and putting required policies in the hands of the people covered by them. They offer an insider a much more concrete comparison than a company’s general statement that it takes compliance seriously.

Exactech later agreed to an $8 million settlement in September 2025 over allegations that it knowingly sold prematurely failing knee components that led to false government claims. That settlement concerned the devices sold and claims caused. The earlier stipulated penalty concerned failures under its agreement.

Agreement enforcement can also end in exclusion from federal programs. The Inspector General excluded La Fuente Ocular Prosthetics in 2018 for failing to repay an overpayment identified by its independent reviewer. It excluded Shreveport Prosthetics in 2021 for failing to engage an independent reviewer to perform quarterly claims reviews.

Individuals can also agree to exclusion in a civil resolution. In the 2021 settlement involving Medical Designs and Sicage, the neurosurgeon whose device interests featured in the Sanford allegations and both companies accepted six years of exclusion. The hospital’s integrity agreement and the surgeon’s exclusion addressed different participants in the same commercial relationship.

FDA Plant Injunctions Address a Different Problem

An FDA plant injunction can stop manufacturing until specified corrective work is completed and the Food and Drug Administration permits operations to resume. Device manufacturing decrees can require an outside expert and the agency’s written permission before the affected operations restart.

That work concerns what the plant makes and whether it can continue making it. Sanford’s independent claims review concerns what the hospital billed. Advanced Bionics’ independent review concerns the preparation of Food and Drug Administration submissions and the standards behind them. The agency involved, the activity reviewed and the obligation imposed explain where an insider’s knowledge fits.

What the Insider Adds to the Review

An insider can connect a compliance report to the conduct it describes. The person who attended a supposed training session, raised a concern about a test or warned about a surgeon’s device income sees something a completed form may leave out.

A Forensic Accountant’s Guide to the Most Potent Federal Laws Used Against Healthcare Fraud, published in the Journal of Forensic and Investigative Accounting in 2020, explains the value of that knowledge:

The paper describes whistleblower cases as a way to bring inside information into enforcement and supplement government resources. In the device cases here, that information came from people close to the work: an engineer at Advanced Bionics, surgeons at Sanford and people who worked in sales at Biotronik.

A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers. We connect the agreement, the conduct you saw and the resulting claims to build your strongest whistleblower case.

When the Reports Leave Out What You Saw

If you work in device sales, engineering or compliance and know what the company’s reports leave out, speak to one of our whistleblower experts about what you saw. We work beside you to build a medical device whistleblower case around the decisions, payments and claims, and bring in medical device fraud whistleblower lawyers who understand physician arrangements and technical submissions. We stay with you from that first account through the case.